AFFY News Alert Affymax (AFFY) 0.0910 12/25/2014 10:59:31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Affymax (AFFY) 0.0910 $AFFY

Affymax up on dividend play
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 10:01AM CST


Affymax reports special cash distribution and new appointment
M2 - Fri Nov 28, 3:01AM CST
The board of directors of Affymax (Other OTC:AFFY), a biopharmaceutical company, on Thursday declared its special distribution of USD0.05 per share of its stock.

Affymax declares cash distribution, names new chief
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:29PM CST


Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards
Business Wire - Wed Nov 26, 3:20PM CST
Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss carryforwards, or NOLs, in relation to the potential limitations under Section 382 of the Internal Revenue Code.

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer
Business Wire - Wed Nov 26, 3:15PM CST
Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share. The special cash distribution will be paid to shareholders of record at the close of business on December 2, 2014, the record date, on or about December 23, 2014. The Board has also appointed Jonathan M. Couchman as a Class I director of the Company and as its President and Chief Executive Officer, and the remaining members of the Board have resigned. The Company, under the leadership of Mr. Couchman, will continue its evaluation of strategic alternatives.

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY
GlobeNewswire - Wed Nov 26, 3:59AM CST
TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX" COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD" .

Xstelos Announces Intention To Vote Against Affymax's Plan Of Liquidation At September 23, 2014 Special Meeting of Shareholders
PR Newswire - Fri Sep 19, 8:15AM CDT
Xstelos Holdings, Inc. and the members of its Schedule 13D group (collectively, the "Xstelos Group" or "we" own approximately 5.0% of the outstanding shares of common stock of Affymax, Inc. (OTC: AFFY) ("Affymax" or the "Company" . Today, the Xstelos Group announced its intention to vote its shares against Affymax's proposed plan of liquidation at the September 23, 2014 Special Meeting of Shareholders.

Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MDGN: 5.19 (-0.02), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), XLRN: 38.80 (+0.80)

Affymax Reports Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:05PM CDT
Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014. The net income for the second quarter of 2014 was $7.2 million (or $0.19 per share) compared to net income of $15.4 million (or $0.41 per share) for the second quarter of 2013.

Glaxo's Label Expansion Plans Marred as Arzerra Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:20PM CDT
GlaxoSmithKline (GSK) and partner Genmab announced disappointing top-line data on their oncology drug, Arzerra.
AGN: 210.12 (+0.95), GSK: 42.85 (+0.11), REGN: 400.12 (+6.07)

Affymax Shares are Trading near Liquidation Value; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 30, 1:00PM CDT
According to the National Kidney Foundation, chronic kidney disease affects over 26 million adults in the U.S., and is caused by diabetes and high blood pressure. As kidney functions deteriorate, the kidney's ability to produce red blood cells declines, and results in anemia. Anemia is a condition in which the patient's blood is deficient in red blood cells and hemoglobin. Kidney dialysis is expensive, and the cost of anemia drugs has been Medicare's single largest drug expenditure, amounting to $3.9 billion in 2007.

AstraZeneca's Olaparib Fails to Impress FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 10:10AM CDT
AstraZeneca (AZN) announced that the FDA's Oncologic Drugs Advisory Committee voted against accelerated approval of olaparib.
AGN: 210.12 (+0.95), AZN: 70.44 (+0.26), REGN: 400.12 (+6.07)

Affymax Board Announces Decision to Dissolve the Company
Business Wire - Tue Jun 24, 3:30PM CDT
Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders as soon as legally permitted and reasonably practicable after paying or making reasonable provision for all known and potential liabilities and other obligations of the Company. Based on the information the Company currently has available, which is subject to change, the Company estimates that the aggregate amount of the distribution to stockholders could be a few cents per share, based on 37,490,095 shares of common stock outstanding as of April 30, 2014 and the remaining cash of approximately $4 million as of May 2014.

OTC Daily Trading Focus List: Axxess Pharma, Inc. Petvivo Holdings, Inc. Integrated Cannabis Solutions, Inc. BreedIT Corp, Affymax, Inc.
PR Newswire Europe - Wed Jun 18, 10:46AM CDT
LONDON, June 18, 2014 /PRNewswire/ --

Affymax terminates Omontys' product collaboration and license agreement with Takeda
M2 - Mon Jun 16, 3:34AM CDT
Biopharmaceutical company Affymax (Other OTC:AFFY) revealed on Friday the termination of its Omontys (peginesatide) product collaboration and license agreement with Takeda Pharmaceutical Company of Osaka, Japan effective 10 September 2014.

Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement
Business Wire - Fri Jun 13, 3:15PM CDT
Affymax, Inc. and Takeda Pharmaceutical Company Limited (Takeda) Osaka, Japan (June 16, 2014) announced today that their Omontys(R) (peginesatide) product collaboration and license agreement will terminate effective September 10, 2014.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 34

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 112

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Crypto: Brian Armstrong on Innovative Payment Solutions

Updated Category News Views 292

Coinbase's Vision for Payments in the Crypto World Brian Armstrong, the CEO of Coinbase Global Inc. (NASDAQ: COIN), is optimistic about the role of payments as a transformative use case within the cryptocurrency landscape. In a recent discussion, he articulated how he believes this sector will significantly evolve, particularly in terms of integrating stablecoins into...

Continue Reading
Veeva Basics Empowering Biotechs to Enhance Efficiency and Growth

Updated Category News Views 185

Veeva Basics Revolutionizes Biotech Operations In today's fast-paced biotech landscape, efficient operations are crucial. Veeva Systems (NYSE: VEEV) has introduced Veeva Basics, a solution now adopted by over 100 emerging biotechs. With this innovative approach, these companies can simplify and standardize their operations, allowing them to focus on what truly matters:...

Continue Reading
Exploring the Rise of Small-Cap Stocks: A 2024 Overview

Updated Category News Views 613

Small-Cap Stocks Lead 2024 Gains In the vibrant market of 2024, small-cap stocks have shined brighter than ever, showcasing remarkable performance that has left traditional blue-chip stocks in their wake. While larger, well-known companies often dominate discussions, smaller firms are making headlines with exhilarating returns. Remarkable Returns in the Market This year,...

Continue Reading
Ridge Street Capital Signs Significant Growth in Lending Sector

Updated Category News Views 206

Ridge Street Capital's Impressive Growth in Investment Lending Ridge Street Capital, a dynamic private lending firm, is celebrating a remarkable achievement in its operation, reporting over 150% growth from one year to the next. This impressive advancement marks the firm as a key player in investment property financing, primarily due to its tailored approach and...

Continue Reading
Kuehn Law Advocates for Sarepta Therapeutics Shareholders

Updated Category News Views 153

Kuehn Law Advocates for Sarepta Therapeutics Shareholders Kuehn Law, PLLC, a law firm dedicated to shareholder litigation, is reaching out to investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) regarding pressing concerns that have surfaced about the company's internal practices. Recent investigations suggest that certain officers and directors possibly did not uphold...

Continue Reading